A 65-year-old womanwith liver cirrhosis complicated by hepatocellular carcinoma lost consciousness due to torsades de pointes with prolongation of the QT-interval after 10 days of treatment with terfenadine. Before terfenadine administration, she had shownneither symptoms of heart disease nor any electrocardiographic abnormalities. Serumelectrolytes were all normal, although the Ca level was near the lower limit of the normal range. After the withdrawal of terfenadine, the QT-interval was normalized and the torsades de pointes disappeared. Since she had liver cirrhosis, the development of torsades de pointes was thought to be attributable to the impairment of hepatic metabolism by terfenadine. (Internal Medicine 34: 92-95, 1995) 
Introduction
Torsades de pointes (Tdp) is a polymorphic ventricular tachycardia which features prolongation of the QT-interval and oscillation of the QRScomplex around the baseline. It is known that Tdp is induced by various drugs ( 1 ) . Terfenadine is a widely used antihistamine drug that has previously been observed to induce Tdp in the United States and Europe (2) (3) (4) . However, only two cases suggestive of terfenadine-related Tdp have been reported in the Japanese literature (5), and in neither was any definite causal relationship between the drug and the arrhythmia established.
Wedescribe herein a patient with liver cirrhosis whodeveloped Tdp 10 days after the start of terfenadine therapy at the recommended clinical dose.
Case Report
The patient was a 65-year-old womanwhopresented on October 19, 1992 with the complaint of episodic loss of consciousness. She did not drink alcohol, but impaired liver function had been detected about 20 years previously, and the diagnosis of liver cirrhosis had been established by laparoscopy in 1984. Since 1988, there had been persistent elevation of the serum bilirubin level. In September 1989, hepatocellular carcinomawas detected in the right lobe of the liver and was subsequently treated with several courses of percutaneous ethanol injection. A hepatitis viral marker survey revealed that she was negative for hepatitis B surface antigen (HBs Ag) but positive for anti-hepatitis C virus antibody (HCV-Ab). She had no history of heart disease, and the electrocardiogram (ECG) obtained in July 1 992 revealed no abnormal findings, including the QT-interval. She had been treated since April 1991 with a preparation knownas sho-saiko-to currently used in Japan for the treatment of various chronic liver diseases consisting of seven crude ingredients extracted from herbs {Bupleuri radix, Pinelliae tuber, Scutellariae radix, Zizyphi fructus, Ginseng radix, Glycyrrhizae radix, and Zingiberis rhizoma) (7.5 g/day) for liver cirrhosis, spironolactone (25 mg/day) for leg edema, and famotidine (20 mg/day), and aldioxa (300 mg/day) for gastritis. Furosemide (20 mg/day) was added to her medication schedule to control leg edema on July 24, 1992. She developed urticaria and began to take terfenadine (120 mg/day) on October?, 1992. Her urticaria resolved, but she twice lost consciousness for about 1 min beginning on October 17 (day 10 of the terfenadine therapy) and was admitted to our hospital on October 19. On admission, she was alart and well oriented. She weighed 50 kg, pulse was regular at 54 per min and blood pressure was 112/56 mmHg.The findings of the physical examination was essentially normal with the exception of slight jaundice and a palpable liver (for 5 cm below the xiphoid process). All findings related to the heart and lungs were corrected QT-interval, QT: QT-interval.
normal, and the neurological findings were also normal.
The ECGobtained on admission showed marked prolongation of the corrected QT-interval (QTc) to 580 mseconds ( Fig.  1 ). Routine hematological and biochemical tests revealed decreased white blood cell and platelet counts, slight elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, elevation of bilirubin, and decreased albumin and cholinesterase (Table 1 ). Both the creatine phosphokinase level and the serum levels of electrolytes were normal, although the Ca level was near lower limit of the normal range. No abnormal findings were detected by echocardiography or on plain chest X-ray films.
Upon admission, all drugs, including terfenadine, were withdrawn, and ECGmonitoring was initiated. An episode of unconsciousness similar to that experienced before admission soon occurred, at which time the ECGshowed oscillation of the QRSaxis around the baseline (Fig. 2) , a finding typical ofTdP. After 30 seconds, the ECGreverted tosinus rhythm, and thepatient regainedconsciousness without any specific treatment. Mg and Ca supplements were administered, although the serum electrolyte levels remained normal, and continuous infusion of lidocaine (1,000 mg over 24 hours) was started. Without atrial or ventricular pacing or B-agonist therapy, no further recurrence of TdP was observed, although the QTc remained prolonged. By the following day, however, the QTc had decreased to 450 mseconds, and it returned to normal thereafter. The lidocaine infusion and Mgand Ca supplementation were discontinued on the 3rd day after QTcnormalization. The clinical course is outlined in Fig. 3 . The patient was discharged on November 17, 1992. The QTc has remained normal and TdP has not occurred again as of this writing, even though the patient has received all of the same drugs she was taking before admission with the exception of terfenadine.
Discussion
Cases of terfenadine-induced TdP have been reported in the United States and Europe (2) (3) (4) . According to these reports, major factors underlying the development of TdP include high drug dose, concomitant use of ketoconazole or erythromycin, and alcoholic liver disease. In Japan, the data regarding adverse reactions to terfenadine published by the Ministry of Health and Welfare include reports of the development of TdP in two patients, one of whomwas undergoing chronic hemodialysis therapy and the other concurrent treatment with erythromycin (5). However, no causal relationship between TdP and terfenadine in these patients was definitely established, nor are there any reports of terfenadine-related TdP in a patient with severe hepatic impairment.
The present patient, whosuffered from liver cirrhosis and hepatocellular carcinoma, showed a normal QT-interval and normal levels of electrolytes including Ca and Mg, but developed TdP after 10 days of treatment with terfenadine at the recommendedclinical dose of 120 mg/day. The elongation of the QT-interval after the terfenadine treatment, together with its normalization and the lack of recurrence of TdP after the withdrawal of terfenadine, strongly suggests that the arrhythmia was an adverse reaction to this drug. Noneof the other drugs, which she had been receiving for a long time before onset of TdP, have been reported to induce TdP. Terfenadine and famotidine are HI and H2 receptor antagonists, respectively, and interaction between these two drugs is unlikely. However, the possibility still remains that any one of these drugs might have interacted with terfenadine, inducing TdP.
Terfenadine is metabolized by the cytochrome P450 system in the liver before excretion (6). Liver disease, especially cirrhosis, reduces the activity of cytochrome P450 and thus increases the blood level of terfenadine (7). This diseaseassociated increase mayhave been the mechanismby which prolongation of the QT-interval and TdP occurred in the present patient.
Most patients with liver disease whodeveloped terfenadinerelated TdPdescribed in the Americanand European reports were considered to be alcohol abusers (8) and may have had hypomagnesemia and/or hypopotassemia or a predisposition to these conditions. Thus, it is possible that the TdP in these patients was not directly related to impaired hepatic metabolism of terfenadine per se. On the other hand, the present patient had nonalcoholic liver cirrhosis with no electrolyte abnormalities (although the Ca level was near the lower limit of the normal range), and impaired metabolism of the drug seems to have played a major role in the development of TdP. In general, TdP is thought to be refractory to therapy other than B-agonists and atrial or ventricular pacing ( 1 ) . Lidocaine is reported to be ineffective in countering TdP (1). However, lidocaine with Ca and Mgsupplements were the only treatments given to the present patient. Although we are unable to offer any explanation of whynormalization of the QT-interval and the suppression of TdP would have been achieved by these treatments alone, the present results suggest that such therapy may sometimes be worth attempting. In Japan, terfenadine treatment has rarely been associated with TdP, but the course in the present patient strongly indicates that it should not be used in patients with liver cirrhosis.
